The company is embarking on a study of up to 2,000 patients to compare its tissue-based targeted sequencing assay with its cell-free DNA test.
Clinical applications for the approach are already at hand, and are poised to expand as companies solidify the clinical validity and utility data behind their platforms.
Cancer-ID is a newly created consortium tasked with validating blood-based biomarkers, such as CTC, cfDNA, and miRNA to bring liquid biopsies into the clinic.
The company said it is shifting focus from demonstrating clinical validity to proving its test can improve patient care and outcomes.
IndivuTest will offer the Sysmex Inostics OncoBEAM test in Germany, Austria, and Switzerland under an exclusive distribution agreement.
The work could have implications not only for noninvasive prenatal testing, but also for oncology for detecting epigenetic changes in circulating tumor DNA.
CAPP Medical, based in Palo Alto, Calif., was founded in October 2013 by Stanford University oncologists and "industry veterans."
With the support of the new funds, the company hopes to launch its NeoLiquid test by the end of this year after completing beta tests.
Vendors and clinicians are struggling with how to deal with the growing number of cases of secondary findings from molecular non-invasive prenatal tests.
Management provided an update on reimbursement and new products in the works for whole-genome karyotyping, carrier screening, and oncology.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.